drugset / Trial / NCT01417195

Menopur Mixed Protocol

NCT01417195

Phase 4 Completed 122 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study was to compare the fertilization rate between the combination of Menopur and Bravelle mixed in the same syringe and Menopur alone, both administered subcutaneously (SC), in subjects undergoing Assisted Reproductive Technology (ART). Additionally the study assessed subjects' ability to mix and store the combination of Menopur and Bravelle and to assess safety of the Menopur and Bravelle combination.

Timeline

Start
2011-07
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bravelle Unknown 75 iu Subcutaneous
Subject Bravelle Unknown 150 iu Subcutaneous
Subject Menopur Protein / enzyme biologic 75 iu Subcutaneous
Subject Menopur Protein / enzyme biologic 150 iu Subcutaneous
Subject Menopur Protein / enzyme biologic 225 iu Subcutaneous

Indications